DK1210374T3 - Humane, monoklonale antistoffer over for prostataspecifikt membranantigen - Google Patents
Humane, monoklonale antistoffer over for prostataspecifikt membranantigenInfo
- Publication number
- DK1210374T3 DK1210374T3 DK00950674T DK00950674T DK1210374T3 DK 1210374 T3 DK1210374 T3 DK 1210374T3 DK 00950674 T DK00950674 T DK 00950674T DK 00950674 T DK00950674 T DK 00950674T DK 1210374 T3 DK1210374 T3 DK 1210374T3
- Authority
- DK
- Denmark
- Prior art keywords
- human
- antibodies
- monoclonal antibodies
- human monoclonal
- prostate
- Prior art date
Links
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 title abstract 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 title abstract 2
- 241001465754 Metazoa Species 0.000 abstract 2
- 230000009261 transgenic effect Effects 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 238000002405 diagnostic procedure Methods 0.000 abstract 1
- 210000004408 hybridoma Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 abstract 1
- 238000005215 recombination Methods 0.000 abstract 1
- 230000006798 recombination Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 238000011830 transgenic mouse model Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/30—Animal model comprising expression system for selective cell killing, e.g. toxins, enzyme dependent prodrug therapy using ganciclovir
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Environmental Sciences (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Plant Pathology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14628599P | 1999-07-29 | 1999-07-29 | |
US15875999P | 1999-10-12 | 1999-10-12 | |
US18808700P | 2000-03-09 | 2000-03-09 | |
PCT/US2000/020247 WO2001009192A1 (fr) | 1999-07-29 | 2000-07-26 | Anticorps monoclonaux humains de l'antigene d'enveloppe prostatique specifique |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1210374T3 true DK1210374T3 (da) | 2007-02-19 |
Family
ID=27386377
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK00950674T DK1210374T3 (da) | 1999-07-29 | 2000-07-26 | Humane, monoklonale antistoffer over for prostataspecifikt membranantigen |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP1210374B1 (fr) |
JP (1) | JP2003508029A (fr) |
KR (1) | KR100733933B1 (fr) |
CN (1) | CN100400547C (fr) |
AT (1) | ATE342282T1 (fr) |
AU (1) | AU783356B2 (fr) |
CA (1) | CA2380783C (fr) |
DE (1) | DE60031279T2 (fr) |
DK (1) | DK1210374T3 (fr) |
ES (1) | ES2277846T3 (fr) |
HK (1) | HK1049015B (fr) |
IL (1) | IL147638A0 (fr) |
MX (1) | MXPA02000961A (fr) |
NZ (1) | NZ517331A (fr) |
WO (1) | WO2001009192A1 (fr) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7105159B1 (en) | 1992-11-05 | 2006-09-12 | Sloan-Kettering Institute For Cancer Research | Antibodies to prostate-specific membrane antigen |
US6569432B1 (en) | 1995-02-24 | 2003-05-27 | Sloan-Kettering Institute For Cancer Research | Prostate-specific membrane antigen and uses thereof |
US7381407B1 (en) | 1996-03-25 | 2008-06-03 | Medarex, Inc. | Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen |
US7560534B2 (en) * | 2000-05-08 | 2009-07-14 | Celldex Research Corporation | Molecular conjugates comprising human monoclonal antibodies to dendritic cells |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
EP2294917A1 (fr) * | 2001-03-22 | 2011-03-16 | Abbott GmbH & Co. KG | Animaux transgéniques exprimant des anticorps spécifiques pour des gènes d'intérêt et leurs utilisations |
CA2464239C (fr) * | 2001-10-23 | 2016-07-12 | Psma Development Company, L.L.C. | Anticorps et multimeres de proteines psma |
US20050215472A1 (en) | 2001-10-23 | 2005-09-29 | Psma Development Company, Llc | PSMA formulations and uses thereof |
NZ534687A (en) * | 2002-01-28 | 2007-10-26 | Medarex Inc | Human monoclonal antibodies to prostate specific membrane antigen (PSMA) seq id 54 |
WO2005070456A2 (fr) * | 2004-01-09 | 2005-08-04 | Millennium Pharmaceuticals, Inc. | Diagnostic et traitement du cancer |
US7348413B2 (en) * | 2004-02-26 | 2008-03-25 | Arius Research Inc. | Cancerous disease modifying antibodies |
CN101124249B (zh) * | 2005-02-18 | 2011-06-29 | 米德列斯公司 | 抗前列腺特异性膜抗原(psma)的人单克隆抗体 |
AU2006214032B2 (en) | 2005-02-18 | 2012-03-08 | E. R. Squibb & Sons, L.L.C. | Monoclonal antibodies against prostate specific membrane antigen (PSMA) lacking in fucosyl residues |
EP1726650A1 (fr) * | 2005-05-27 | 2006-11-29 | Universitätsklinikum Freiburg | Anticorps monoclonaux et fragments d'anticorps monocaténaires contre l'antigène spécifique de surface membranaire de la prostate |
WO2007014278A2 (fr) | 2005-07-25 | 2007-02-01 | Trubion Pharmaceuticals, Inc. | Reduction de lymphocytes b au moyen de molecules de liaison specifique de cd37 et specifique de cd20 |
WO2007146968A2 (fr) | 2006-06-12 | 2007-12-21 | Trubion Pharmaceuticals, Inc. | Protéines de liaison monocaténaires polyvalentes dotées d'une fonction d'effecteur |
CN101158687B (zh) * | 2007-06-11 | 2012-09-05 | 吉林大学 | 多肽psa2在制备前列腺癌诊断试剂盒中的应用 |
CN102099377A (zh) | 2008-04-11 | 2011-06-15 | 新兴产品开发西雅图有限公司 | Cd37免疫治疗剂及其与双功能化学治疗剂的联合 |
PL2326350T3 (pl) | 2008-09-08 | 2014-03-31 | Psma Dev Company L L C | Związki do zabijania eksprymujących PSMA, opornych na taksan komórek rakowych |
HUE030090T2 (en) * | 2008-10-01 | 2017-04-28 | Amgen Res (Munich) Gmbh | Species specific PSMAxCD3 bispecific single chain antibody |
CN101891818B (zh) * | 2009-01-16 | 2012-07-25 | 中国人民解放军第四军医大学 | 抗人前列腺特异性膜抗原胞外区单链抗体及其应用 |
WO2012143495A2 (fr) | 2011-04-21 | 2012-10-26 | Bayer Intellectual Property Gmbh | Nouveaux conjugués liant-principe actif (adc) et leur utilisation |
WO2012145714A2 (fr) | 2011-04-22 | 2012-10-26 | Emergent Product Development Seattle, Llc | Protéines de liaison à un antigène membranaire spécifique de la prostate et compositions et procédés associés |
CA2885340C (fr) | 2012-10-12 | 2016-11-08 | Spirogen Sarl | Pyrrolobenzodiazepines et leurs conjugues |
KR102066319B1 (ko) | 2013-03-13 | 2020-01-14 | 메디뮨 리미티드 | 피롤로벤조디아제핀 및 그의 컨쥬게이트 |
US10117943B2 (en) | 2013-05-03 | 2018-11-06 | Yale University | Synthetic antibody mimetic compounds (SYAMS) targeting cancer, especially prostate cancer |
EP3086814B1 (fr) | 2013-12-23 | 2020-06-24 | Bayer Pharma Aktiengesellschaft | Conjugués de liants (conjugué anticorps-médicament) comprenant des inhibiteurs de la protéine kinésine du fuseau |
JP6531166B2 (ja) | 2014-09-10 | 2019-06-12 | メドイミューン・リミテッドMedImmune Limited | ピロロベンゾジアゼピン及びそのコンジュゲート |
AU2016282723B2 (en) | 2015-06-22 | 2021-09-23 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates (ADCs) and antibody prodrug conjugates (APDCs) with enzymatically cleavable groups |
CN108367004B (zh) | 2015-09-21 | 2022-09-13 | 阿帕特夫研究和发展有限公司 | Cd3结合多肽 |
WO2017060322A2 (fr) | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Conjugué anticorps-médicament (adc) inhibiteur de ptefb |
EP3432934B1 (fr) | 2016-03-24 | 2022-02-23 | Bayer Pharma Aktiengesellschaft | Promedicaments d'agents actifs cytotoxiques comprenant des groupes clivables par enzymes |
RU2018137110A (ru) | 2016-04-13 | 2020-05-13 | Оримабс Лтд. | Антитела против psma и их применение |
EP3919518A1 (fr) | 2016-06-15 | 2021-12-08 | Bayer Pharma Aktiengesellschaft | Conjugués anticorps-médicament spécifiques (adc) avec inhibiteurs de ksp et des anticorps anti-cd123 |
WO2018069289A1 (fr) | 2016-10-11 | 2018-04-19 | Medimmune Limited | Conjugués anticorps-médicament associés à des agents thérapeutiques à médiation immunitaire |
IL310558A (en) | 2016-12-21 | 2024-03-01 | Bayer Pharma AG | Drug-antibody conjugates with enzymatically cleavable groups |
CN110072556B (zh) | 2016-12-21 | 2023-05-02 | 拜耳制药股份公司 | 具有ksp抑制剂的特异性抗体药物缀合物(adc) |
CN110312533B (zh) | 2016-12-21 | 2023-11-03 | 拜耳公司 | 具有酶促可裂解的基团的细胞毒性活性剂的前药 |
ES2921775T3 (es) * | 2017-03-30 | 2022-08-31 | Ecs Progastrin Sa | Composiciones y métodos para detectar y tratar el cáncer de próstata que utilizan la molécula de unión a progastrina |
CN112119157A (zh) | 2018-03-06 | 2020-12-22 | 宾夕法尼亚大学董事会 | 前列腺特异性膜抗原car及其使用方法 |
US20220111065A1 (en) | 2018-05-23 | 2022-04-14 | Adc Therapeutics Sa | Molecular adjuvant |
US11976131B2 (en) | 2018-07-31 | 2024-05-07 | Heidelberg Pharma Research Gmbh | Humanized antibodies against PSMA |
CN110297093B (zh) * | 2019-03-18 | 2022-04-22 | 山西瑞豪生物科技有限公司 | 一种检测人免疫球蛋白g4的方法和试剂盒 |
US20230372528A1 (en) | 2020-10-16 | 2023-11-23 | University Of Georgia Research Foundation, Inc. | Glycoconjugates |
GB202102396D0 (en) | 2021-02-19 | 2021-04-07 | Adc Therapeutics Sa | Molecular adjuvant |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS649192A (en) * | 1987-07-01 | 1989-01-12 | Suzutec Co Ltd | Grain tank for track transport |
US6300129B1 (en) * | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
US5489525A (en) * | 1992-10-08 | 1996-02-06 | The United States Of America As Represented By The Department Of Health And Human Services | Monoclonal antibodies to prostate cells |
EP0823941A4 (fr) * | 1995-04-28 | 2001-09-19 | Abgenix Inc | Anticorps humains derives de xeno-souris immunisees |
ATE318147T1 (de) * | 1996-03-25 | 2006-03-15 | Medarex Inc | Spezifische monoklonale antikörperfür die extrazelluläre domäne von protasta-spezifischem membranantigen |
US6150508A (en) * | 1996-03-25 | 2000-11-21 | Northwest Biotherapeutics, Inc. | Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen |
US6107090A (en) * | 1996-05-06 | 2000-08-22 | Cornell Research Foundation, Inc. | Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains |
JP4082740B2 (ja) * | 1997-02-28 | 2008-04-30 | キリンファーマ株式会社 | 内因性遺伝子が破壊されている分化多能性保持細胞 |
CA2286090C (fr) * | 1997-04-30 | 2013-01-08 | Hybritech Incorporated | Formes d'antigene a specificite prostatique (asp) et leurs procedes de detection |
-
2000
- 2000-07-26 WO PCT/US2000/020247 patent/WO2001009192A1/fr active IP Right Grant
- 2000-07-26 AT AT00950674T patent/ATE342282T1/de not_active IP Right Cessation
- 2000-07-26 MX MXPA02000961A patent/MXPA02000961A/es not_active Application Discontinuation
- 2000-07-26 ES ES00950674T patent/ES2277846T3/es not_active Expired - Lifetime
- 2000-07-26 IL IL14763800A patent/IL147638A0/xx unknown
- 2000-07-26 CN CNB008131651A patent/CN100400547C/zh not_active Expired - Fee Related
- 2000-07-26 CA CA002380783A patent/CA2380783C/fr not_active Expired - Fee Related
- 2000-07-26 DE DE60031279T patent/DE60031279T2/de not_active Revoked
- 2000-07-26 KR KR1020027001187A patent/KR100733933B1/ko not_active IP Right Cessation
- 2000-07-26 AU AU63745/00A patent/AU783356B2/en not_active Ceased
- 2000-07-26 NZ NZ517331A patent/NZ517331A/en unknown
- 2000-07-26 EP EP00950674A patent/EP1210374B1/fr not_active Revoked
- 2000-07-26 JP JP2001513998A patent/JP2003508029A/ja active Pending
- 2000-07-26 DK DK00950674T patent/DK1210374T3/da active
-
2002
- 2002-12-05 HK HK02108881.3A patent/HK1049015B/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
IL147638A0 (en) | 2002-08-14 |
KR100733933B1 (ko) | 2007-07-03 |
ES2277846T3 (es) | 2007-08-01 |
HK1049015A1 (en) | 2003-04-25 |
JP2003508029A (ja) | 2003-03-04 |
CA2380783A1 (fr) | 2001-02-08 |
CA2380783C (fr) | 2009-01-27 |
WO2001009192A9 (fr) | 2002-09-12 |
CN100400547C (zh) | 2008-07-09 |
AU6374500A (en) | 2001-02-19 |
WO2001009192A1 (fr) | 2001-02-08 |
NZ517331A (en) | 2004-02-27 |
EP1210374B1 (fr) | 2006-10-11 |
DE60031279D1 (de) | 2006-11-23 |
AU783356B2 (en) | 2005-10-20 |
KR20020047099A (ko) | 2002-06-21 |
ATE342282T1 (de) | 2006-11-15 |
CN1387539A (zh) | 2002-12-25 |
MXPA02000961A (es) | 2003-08-20 |
EP1210374A1 (fr) | 2002-06-05 |
DE60031279T2 (de) | 2007-05-16 |
HK1049015B (zh) | 2007-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1210374T3 (da) | Humane, monoklonale antistoffer over for prostataspecifikt membranantigen | |
LTPA2021514I1 (fr) | ||
DK1282646T3 (da) | Humane monoklonale antistoffer mod dendritiske celler | |
DK1425389T3 (da) | Interleukin-15-(IL-15)-specifikke humane antistoffer | |
WO2003040169A3 (fr) | Anticorps monoclonaux humains diriges contre les cellules dendritiques | |
NO20053417L (no) | Humane monoklonale antistoffer mot interleukin 8 (IL-8) | |
DE60037896D1 (de) | Menschliche antikörper gegen her2/neu | |
WO2003064606A3 (fr) | Anticorps monoclonaux humains de l'antigene d'enveloppe prostatique specifique (psma) | |
ATE531731T1 (de) | Humane monoklonale antikörper gegen den epidermal-growth-factor-rezeptor (egfr) | |
TW200500378A (en) | Human antibodies specific for interleukin 15 (IL-15) | |
MXPA05012571A (es) | Anticuerpos monoclonales humanos contra el antigeno protector de bacillus anthracis. | |
RS20050724A (en) | Human antibodies specific for interleukin 15(il-15) |